Lab
University of Penn-Medical Group
University of Penn-Medical Group was paid $1.33M by Medicaid between Mar 2020 and Dec 2024, across 73 billing codes. Its largest line is 80050, General health panel — 15% of everything it billed.
33Billing provider infoUNIVERSITY OF PENN-MEDICAL GROUP
PHILADELPHIA, PA 19104
PHILADELPHIA, PA 19104
33aNPI1184012569assigned 01/07/2015
33bProvider typeClinical Medical Laboratory
28Total paid$1.33M
24GClaims100,132
24DCodes billed73
24AFirst – last monthMar 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Pennsylvania
Rank by total paid#23 of 95
Median peer was paid$153K
This provider vs. median8.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JACKSON, CHANTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,272 | $80K | |
| 2021 | 24,822 | $434K | |
| 2022 | 25,681 | $304K | |
| 2023 | 22,157 | $240K | |
| 2024incomplete | 23,200 | $270K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80050 | General health panel | 15% | 6,169 | 5,911 | $197K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 2,706 | 2,605 | $166K |
| 80061 | Lipid panel | 7.0% | 9,598 | 9,271 | $93K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 5.0% | 3,119 | 3,016 | $66K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.3% | 3,303 | 3,130 | $57K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.4% | 108 | 106 | $45K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 3,377 | 3,194 | $44K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.6% | 2,012 | 1,921 | $35K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.5% | 1,116 | 1,082 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.5% | 8,308 | 7,933 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.4% | 4,409 | 4,196 | $32K |
| 80053 | Comprehensive metabolic panel | 2.2% | 3,408 | 3,262 | $30K |
61 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.2% | 2,705 | $29K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.2% | 782 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.1% | 1,821 | $28K |
| 88237 | 1.9% | 134 | $25K | |
| 86803 | 1.9% | 1,738 | $25K | |
| 82607 | 1.8% | 3,375 | $24K | |
| 87631 | 1.8% | 177 | $23K | |
| 85027 | 1.7% | 5,176 | $22K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 385 | $22K |
| 84153 | 1.5% | 844 | $20K | |
| 84466 | 1.5% | 1,918 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 2,483 | $17K |
| 82728 | 1.3% | 2,242 | $17K | |
| 86480 | 1.2% | 272 | $16K | |
| 82043 | 1.2% | 2,785 | $16K | |
| 82570 | 1.1% | 2,949 | $14K | |
| 87536 | 1.0% | 130 | $14K | |
| 82746 | <1% | 2,532 | $13K | |
| 87088 | <1% | 1,901 | $13K | |
| 83540 | <1% | 1,951 | $10K | |
| 86592 | <1% | 2,370 | $8K | |
| 84439 | <1% | 1,644 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,100 | $7K |
| 86360 | <1% | 109 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 40 | $6K |
| 83735 | <1% | 1,021 | $5K | |
| 86359 | <1% | 109 | $5K | |
| 86706 | <1% | 504 | $4K | |
| 81001 | <1% | 2,496 | $4K | |
| 88264 | <1% | 31 | $4K | |
| 88291 | <1% | 136 | $4K | |
| 87077 | <1% | 616 | $4K | |
| 87481 | <1% | 92 | $4K | |
| 87340 | <1% | 322 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 30 | $3K |
| 80364 | <1% | 94 | $2K | |
| 87186 | <1% | 352 | $2K | |
| 81003 | <1% | 1,421 | $2K | |
| 81513 | <1% | 104 | $2K | |
| 80076 | <1% | 370 | $2K | |
| 85610 | <1% | 553 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 27 | $2K |
| 87467 | <1% | 286 | $2K | |
| 87081 | <1% | 279 | $2K | |
| 88141 | <1% | 170 | $2K | |
| 85652 | <1% | 486 | $1K | |
| 86038 | <1% | 108 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $896.66 |
| 84403 | <1% | 12 | $370.68 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16 | $359.31 |
| 83721 | <1% | 53 | $333.84 | |
| 84481 | <1% | 13 | $102.83 | |
| 83690 | <1% | 15 | $59.00 | |
| 81015 | <1% | 25 | $55.96 | |
| 87070 | <1% | 15 | $55.76 | |
| 87205 | <1% | 16 | $37.22 | |
| 84550 | <1% | 13 | $31.60 | |
| 85007 | <1% | 25 | $26.87 | |
| 85045 | <1% | 15 | $22.98 | |
| 86140 | <1% | 13 | $14.58 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 83 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACKSON, CHANTE (ENROLLMENT LEAD)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.